AQST Q3 2024 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$14M+4.2% YoY

Gross Profit

$9M67.2% margin

Operating Income

-$8M-61.2% margin

Net Income

-$12M-85.0% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

-32.6%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$110M

Total Liabilities

$155M

Stockholders' Equity

-$45M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$13M	+4.2%
Gross Profit	$9M	$8M	+11.0%
Operating Income	-$8M	-$2M	-248.8%
Net Income	-$12M	-$2M	-465.6%

Revenue Segments

Manufacture and Supply Revenue

$11M79%

License and Royalty Revenue

$2M16%

Co-Development and Research Fees

$492,0004%

Manufactured Product, Other

$217,0002%

Geographic Segments

UNITED STATES

$11M78%

Non-US

$3M22%